Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2452)	8/28/1999 4:19:00 AM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

"For the nine months ended 3/31/99, net sales rose 37% to $66.6 million. Net income rose 12% to $11.6 million. Revenues reflect the acquisition of Genzyme's research products business and increased sales of R&D Systems' cytokines, antibodies and immunoassay kits. From the Techne profile on Yahoo biz.yahoo.com "For the three months ended June 30, 1999,...R&D Systems' Biotechnology Division net sales increased 42% to $14,963,227 from $10,539,116 and R&D Europe's net sales increased 24% to $5,819,845 from $4,705,990. R&D Systems' Hematology Division net sales also increased 6% to $3,529,119 from $3,337,860." "For the twelve months ended June 30, 1999, ...R&D Systems' Biotechnology Division net sales increased 46% to $54,960,816 from $37,713,747 and R&D Europe's net sales increased 31% to $23,266,337 from $17,793,598. R&D Systems' Hematology Division net sales also increased 8% to $12,673,544 from $11,784,093." biz.yahoo.com

To: Walter Morton who wrote (2452)	8/28/1999 11:36:00 AM
From: PeterR1700	Read Replies (2) \| Respond to of 2742

Walter - since day one, I've never really "gotten" my brain around cist and its future. Bought it on a "tip" - cheap shares and didn't dip my toes in too deep. So, I really don't have a clue what the company is about with the exception of strange (IMO) occurances such as excessive compensation, failed mergers, products that don't get approved etc. If none of the above is true, my short-term memory is too blame. Peter